Loading…
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $-72M | $-64M | $-74M | 43.6% | 336.9% | - |
| 2024 | $1M | $-50M | $-44M | $12M | 50.1% | - | - |
| 2023 | $0M | $-34M | $-29M | $-34M | 61.9% | - | - |
| 2022 | $0M | $-19M | $-18M | $-20M | 93.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 1.49 | 6.50 |
| Operating Expense | 19.76 | 34.79 | 53.54 | 81.18 |
| Operating Income | -19.76 | -34.79 | -52.05 | -74.68 |
| EBITDA | -19.32 | -33.60 | -50.48 | -72.36 |
| EBIT | -19.76 | -34.79 | -52.05 | -74.68 |
| Pretax Income | -17.93 | -28.64 | -43.98 | -63.73 |
| Net Income | -17.93 | -28.64 | -43.98 | -63.73 |
| Net Income Common Stockholders | -17.93 | -28.64 | -43.98 | -63.73 |
| Total Expenses | 19.76 | 34.79 | 53.54 | 81.18 |
| Interest Income | 1.65 | 5.38 | 8.10 | 11.01 |
| Research And Development | 14.30 | 25.92 | 40.95 | 67.45 |
| Selling General And Administration | 5.11 | 7.68 | 11.31 | 12.60 |
| Normalized EBITDA | -19.52 | -34.40 | -50.47 | -72.36 |
| Normalized Income | -18.13 | -29.44 | -43.97 | -63.73 |
| Basic EPS | -0.51 | -0.82 | -1.26 | 0 |
| Diluted EPS | -0.51 | -0.82 | -1.26 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.20 | 0.80 | -0.01 | 0 |
| Total Unusual Items Excluding Goodwill | 0.20 | 0.80 | -0.01 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -17.93 | -28.64 | -43.98 | -63.73 |
| Reconciled Depreciation | 0.45 | 1.12 | 1.57 | 2.33 |
| Net Interest Income | 1.65 | 5.38 | 8.10 | 11.01 |
| Net Income From Continuing And Discontinued Operation | -17.93 | -28.64 | -43.98 | -63.73 |
| Total Operating Income As Reported | -19.76 | -34.79 | -52.05 | -74.68 |
| Diluted Average Shares | 34.86 | 34.86 | 34.86 | 0 |
| Basic Average Shares | 34.86 | 34.86 | 34.86 | 0 |
| Diluted NI Availto Com Stockholders | -17.93 | -28.64 | -43.98 | -63.73 |
| Net Income Including Noncontrolling Interests | -17.93 | -28.64 | -43.98 | -63.73 |
| Net Income Continuous Operations | -17.93 | -28.64 | -43.98 | -63.73 |
| Other Income Expense | 0.19 | 0.78 | -0.03 | -0.06 |
| Other Non Operating Income Expenses | -0.01 | -0.02 | -0.03 | -0.06 |
| Gain On Sale Of Security | 0.20 | 0.80 | -0.01 | 0 |
| Net Non Operating Interest Income Expense | 1.65 | 5.38 | 8.10 | 11.01 |
| Interest Income Non Operating | 1.65 | 5.38 | 8.10 | 11.01 |
| Depreciation Amortization Depletion Income Statement | 0.36 | 1.20 | 1.28 | 1.13 |
| Depreciation And Amortization In Income Statement | 0.36 | 1.20 | 1.28 | 1.13 |
| Depreciation Income Statement | 0.36 | 1.20 | 1.28 | 1.13 |
| General And Administrative Expense | 5.11 | 7.68 | 11.31 | 12.60 |
| Other Gand A | 2.18 | 2.92 | 5.16 | 4.92 |
| Salaries And Wages | 2.93 | 4.76 | 6.14 | 7.68 |
| Operating Revenue | 0 | 0 | 1.49 | 6.50 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aktis Oncology, Inc.this co. | AKTS | $1.0B | - | -0.12 | 43.6% | -15.93 |
| Teladoc Health, Inc. | TDOC | $1.1B | - | 0.77 | -14.5% | 39.94 |
| IRADIMED CORPORATION | IRMD | $1.1B | 47.83 | 11.31 | 23.8% | 37.30 |
| The Pennant Group, Inc. | PNTG | $1.1B | 36.56 | 3.22 | 7.9% | 25.85 |
| Septerna, Inc. | SEPN | $1.1B | - |
| 2.75 |
| -12.8% |
| -8.66 |
| Omeros Corporation | OMER | $1.0B | - | -8.61 | 2.8% | -9.24 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.0B | - | 73.41 | 4.0% | 31.98 |
| Collegium Pharmaceutical, Inc. | COLL | $1.0B | 16.75 | 3.49 | 20.8% | 4.08 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $1.0B | 9.72 | 1.21 | 12.4% | 6.78 |
| Peer Median | - | 26.66 | 2.99 | 6.0% | 16.31 | |